Placebo-Controlled Study of Mometasone Furoate [Nasonex] Nasal Spray (MFNS) 200 Mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR).

Trial Profile

Placebo-Controlled Study of Mometasone Furoate [Nasonex] Nasal Spray (MFNS) 200 Mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Mometasone (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 01 Mar 2010 Pooled results of this and an identically designed trial presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) held on 26 Feb - 2 Mar 2010, in New Orleans, Los Angeles, USA.
    • 20 Nov 2009 Actual patient number (333) added as reported by ClinicalTrials.gov.
    • 05 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top